Today, the Scottish Medicines Consortium (SMC) has announced that it has rejected olaparib (Lynparza).
This decision comes after both the Cancer Drugs Fund and NICE rejected the drug on cost grounds in England and Wales. Olaparib was being assessed as a maintenance treatment of relapsed platinum-sensitive ovarian cancer, for women with a BRCA1 or 2 mutation, and whose disease has responded to second-line or subsequent platinum-based chemotherapy – around 400 women a year.
The decision means that the treatment will not be made available to women with ovarian cancer in Scotland.
Responding to the decision, Dr Simon Newman, Director of Research for Target Ovarian Cancer, said: “We’re extremely disappointed by this decision. There are very few treatment options for women with ovarian cancer, and it is essential that we see more new drugs funded. We are urging the SMC and AstraZeneca to work together to come to an agreement and make this treatment available to women with ovarian cancer.”